The research, led by Penghui Song, Lijuan Ma, and Dong Yan and published in PLOS Genetics, set out to answer a deceptively simple question: what does Mettl16 actually do in Drosophila melanogaster? In mammals, METTL16 is essential for embryonic development, and its loss is lethal, largely because it modifies a specific structural RNA involved in splicing and helps regulate the synthesis of S-adenosylmethionine, the universal methyl donor of the cell. Because flies lack some of the mammalian regulatory features, the expectation was that Mettl16 might behave similarly, or perhaps be dispensable altogether. The team generated flies carrying loss-of-function mutations in the Mettl16 gene and watched what happened across the entire life cycle. The result was unexpected: unlike in mammals, Mettl16 mutant flies survived to adulthood. They were alive, but far from well, displaying a constellation of developmental and behavioral abnormalities that hinted at a deep, if selective, importance of this enzyme.

The most dramatic phenotype was sterility. Both male and female mutants were completely infertile, and microscopic examination of their gonads revealed severe defects in gametogenesis, the intricate choreography by which germ cells divide, specialize, and mature into sperm and eggs. This was a crucial clue. Fertility is one of the most sensitive readouts of RNA metabolism, because germ cells undergo some of the most dramatic transcriptional and developmental transitions in any tissue. The fact that Mettl16 loss brought the entire reproductive program to a grinding halt suggested that the enzyme supports specific, non-redundant steps in the formation of gametes, rather than serving as a general housekeeping factor that cells could easily compensate for.

To pinpoint where things went wrong, the researchers traced germ cell development stage by stage. Remarkably, Mettl16 mutant germ cells were able to navigate the early milestones without obvious catastrophe: they completed the mitotic divisions that expand the germline population and progressed through meiosis, the specialized reductional division that generates haploid cells. The breakdown came later, during spermiogenesis, the transformation of round spermatids into the sleek, elongated, motile sperm that define male fertility. In the mutants, spermatid elongation faltered and individualization, the process by which each spermatid is sculpted, compacted, and encased in its own membrane sheath, failed to proceed properly. This stage-specific failure is telling, because spermatid elongation and individualization demand massive, precisely timed remodeling of the cytoskeleton, of chromatin, and of RNA populations inherited from earlier stages. Mettl16 therefore appears to be required for the late maturation program of sperm rather than for the fundamental mechanics of cell division.

Where does the enzyme live inside the cell, and what does it do when it gets there? The team tagged Mettl16 with green fluorescent protein and found that the fusion protein localized predominantly to the nucleus, consistent with a role in nuclear RNA processing rather than in the cytoplasmic control of translation. To test whether Mettl16 loss broadly crippled protein synthesis, the researchers examined wing disc epithelial cells, a classic Drosophila model tissue, and found that global protein production was not impaired in the absence of the enzyme. This observation carries real weight. If Mettl16 were a major regulator of mRNA translation, its removal should have left a visible signature on the protein output of the cell. Instead, the data pointed toward a narrower, more targeted function, in which only a specific set of RNA substrates depends on Mettl16 activity.

That selectivity was confirmed at the level of the transcriptome-wide methylome. Using MeRIP-Seq, a technique that immunoprecipitates methylated RNA fragments and maps them back to the genome, the researchers compared the m6A landscape of normal flies with that of Mettl16 mutants. The comparison produced a striking contrast. When Mettl3 is lost, the effect on m6A is broad, sweeping away the modification from a large fraction of transcripts across the transcriptome. Mettl16 loss, by comparison, altered m6A on only a small subset of RNAs. This result reframes the two enzymes as complementary writers with distinct substrate preferences: Mettl3 acts as the bulk methyltransferase decorating thousands of messages, while Mettl16 behaves as a specialist, placing marks on a curated list of targets whose identity appears central to the phenotypes observed in the mutant flies.

Among those targets, one stood out with particular clarity: U6 snRNA, the small nuclear RNA that forms the catalytic heart of the spliceosome, the molecular machine that removes intervening sequences from pre-messenger RNAs. The team demonstrated that Mettl16 physically interacts with U6 snRNA and is required for its m6A modification. This finding connects the fly enzyme to one of the most conserved functions described for METTL16 in other organisms, the methylation of U6, and it immediately suggested a mechanism by which the enzyme could exert widespread downstream effects. Splicing is the process that stitches together the coding segments of genes, and alternative splicing allows a single gene to produce multiple protein variants. If Mettl16 fails to methylate U6, the spliceosome’s precision could be subtly compromised, reshuffling the splicing patterns of many genes even though only a handful of transcripts lose their m6A marks directly.

That prediction held up. The researchers found that Mettl16 mutants display widespread alterations in alternative splicing, meaning that the way numerous pre-messenger RNAs are assembled into mature messages changes throughout the animal. This splicing dysregulation provides a plausible mechanistic bridge between the enzyme’s narrow biochemical footprint and its pleiotropic developmental consequences. Genes required for spermatid elongation, for oogenesis, and for normal behavior could each be mis-spliced in the mutant, producing protein isoforms that are truncated, unstable, or functionally altered. The picture that emerges is one of indirect amplification: a single, targeted RNA modification on a core splicing component ripples outward into broad changes in gene expression, which in turn manifest as the sterile, behaviorally abnormal flies observed in the study.

The evolutionary implications of the work are equally compelling. Comparing flies with mammals reveals a remarkable divergence in biological logic. In mammals, METTL16 is indispensable, its loss lethal during embryogenesis, whereas in flies the enzyme is dispensable for viability but essential for reproduction and normal development. This kind of comparative data helps researchers understand how the epitranscriptome has been rewired across hundreds of millions of years of evolution, with the same chemical modification and the same family of writer enzymes being deployed in different tissues and at different developmental checkpoints depending on the organism. It also cautions against assuming that findings from one model system translate directly to another, a lesson with practical consequences for biomedical research that relies on m6A biology as a therapeutic target.

For the growing community of scientists studying RNA modifications, the Drosophila study adds an important piece to the puzzle of how m6A writers divide their labor. Mettl3 emerges as the generalist, methylating a broad swath of the transcriptome, while Mettl16 operates as a specialist whose most clearly defined substrate is the U6 snRNA at the heart of the splicing machinery. The pleiotropic phenotypes of Mettl16 mutants, from failed spermatid individualization to behavioral defects, most likely stem from the combination of direct m6A deposition on specific target transcripts and the indirect consequences of U6-dependent splicing regulation. As epitranscriptomics moves from cataloging modifications toward understanding their causal roles in development and disease, this fly work demonstrates that even a small subset of methylated RNAs, when left unmodified, can be enough to derail some of the most elaborate programs an animal ever runs, including the construction of the next generation itself.

Subject of Research: The role of the m6A methyltransferase Mettl16 in Drosophila development, fertility, and RNA splicing regulation

Article Title: Role of the m 6 A methyltransferase Mettl16 in Drosophila development

Article References: Song, P., Ma, L., & Yan, D. (2026). Role of the m6A methyltransferase Mettl16 in Drosophila development. PLOS Genetics, 22(9), e1012317. https://doi.org/10.1371/journal.pgen.1012317

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012317

Keywords: m6A, Mettl16, Drosophila, epitranscriptomics, RNA methylation, U6 snRNA, alternative splicing, gametogenesis, spermatid individualization, PLOS Genetics, methyltransferase, developmental biology

The research focuses on N6-methyladenosine, or m6A, the most abundant internal chemical modification found on messenger RNA in eukaryotic cells. Rather than altering the genetic code itself, m6A marks act like adjustable dimmer switches, influencing how efficiently a given transcript is processed, exported, translated, or degraded. METTL16 is one of the key writer enzymes of this system, and previous work had already implicated it in a range of cancers, from gastric and pancreatic tumors to bladder carcinoma, where it can either promote or suppress malignancy depending on the tissue context. The new study set out to determine what METTL16 does in colorectal cancer, and the answer turned out to involve a surprising metabolic detour.

The team began by measuring METTL16 levels in clinical colorectal cancer samples and in colorectal cancer cell models, using immunohistochemistry, quantitative PCR and western blotting. Across these analyses, METTL16 was consistently elevated in tumor tissue compared with healthy references. That observation raised an obvious question: was the enzyme simply a passenger, or was it actively driving the disease? To find out, the researchers used short hairpin RNA to knock down METTL16 in colorectal cancer cells and then ran a battery of functional assays, including CCK-8 viability tests, EdU proliferation assays, wound healing experiments and transwell migration and invasion chambers.

The results were striking. When METTL16 was depleted, the malignant behavior of the cancer cells collapsed on multiple fronts: they proliferated more slowly, migrated less aggressively and invaded less effectively. But the most intriguing finding emerged when the team introduced a co-culture system in which colorectal cancer cells were grown alongside CD8-positive T cells, the cytotoxic soldiers of the adaptive immune system. In the presence of METTL16-depleted tumor cells, the T cells proliferated more vigorously and secreted higher levels of three critical effector molecules: interferon-gamma, interleukin-2 and granzyme B. In other words, silencing METTL16 in the tumor made the immune cells surrounding it measurably more lethal.

This suggested that METTL16 was not merely a growth promoter inside the tumor cell but also an architect of immune evasion, helping the cancer hide from cytotoxic T lymphocytes. The next challenge was to identify the molecular bridge connecting an RNA modification enzyme to tumor metabolism and T cell function. The researchers’ attention turned to branched-chain amino acid transaminase 1, or BCAT1, an enzyme that catalyzes the first step in the breakdown of the branched-chain amino acids leucine, isoleucine and valine. BCAT1 had previously been flagged as a risk factor in multiple cancers through pan-cancer analyses, and accumulating evidence indicates that branched-chain amino acid availability can reprogram glucose metabolism in CD8-positive T cells in ways that enhance their anti-tumor effector function.

Using a trio of molecular techniques, the team dissected how METTL16 controls BCAT1. RNA immunoprecipitation showed a physical association between METTL16 and the BCAT1 transcript. Methylated RNA immunoprecipitation, or MeRIP, revealed that METTL16 deposits m6A marks on BCAT1 mRNA. And mRNA stability assays demonstrated the functional consequence: the m6A modification stabilized the BCAT1 message, extending its lifespan inside the cell and thereby boosting BCAT1 protein production. Liquid chromatography tandem mass spectrometry metabolomics then confirmed that this increase in BCAT1 drove enhanced catabolism of branched-chain amino acids within the tumor cells.

To prove that BCAT1 was the critical downstream mediator rather than an incidental bystander, the researchers performed rescue experiments. When they forced overexpression of BCAT1 in METTL16-depleted colorectal cancer cells, the suppressive effects of the knockdown were largely reversed: the cells regained their malignant characteristics, and the CD8-positive T cells in the co-culture system lost their enhanced proliferative and cytotoxic responses. This gain-of-function experiment established BCAT1 as the linchpin connecting METTL16’s RNA modification activity to both tumor progression and immune suppression, effectively closing the mechanistic loop.

The story then moved from the dish to the living organism. In a xenograft mouse model, depletion of METTL16 significantly inhibited tumor growth and reduced Ki-67, a well-established marker of cellular proliferation, within the tumors. Critically, the METTL16-deficient tumors also showed enhanced infiltration by CD8-positive T cells and elevated levels of T cell effector molecules, mirroring the in vitro findings and confirming that the enzyme’s influence on anti-tumor immunity operates within the complex microenvironment of a living tumor. The convergence of cell culture, molecular biology, metabolomics and animal data gives the study an unusually complete chain of evidence for a single mechanistic axis.

The implications reach well beyond colorectal cancer. The work adds to a growing body of literature showing that RNA modifications, once considered little more than molecular noise, are master regulators of cancer metabolism and tumor immunology. Other m6A machinery components, such as the methyltransferase METTL3 and the reader protein YTHDF1, have been shown to modulate immune evasion in colorectal tumors, and METTL16 itself has previously been linked to PD-L1-mediated immune escape. What makes the new findings particularly compelling is the metabolic dimension: by consuming branched-chain amino acids through BCAT1, high-METTL16 tumors may starve infiltrating T cells of nutrients they need to sustain their attack, a form of metabolic competition that complements classical immune checkpoint mechanisms.

For patients, the study suggests several potential avenues. METTL16 or BCAT1 could serve as biomarkers to identify colorectal tumors that are particularly adept at suppressing T cell immunity, helping clinicians select candidates for immunotherapy combinations. More ambitiously, pharmacological inhibitors of METTL16 or BCAT1, or dietary and metabolic strategies that manipulate branched-chain amino acid availability, could in principle be combined with checkpoint blockade to re-energize exhausted T cells. Such applications remain distant, and the study’s findings will need validation in larger cohorts and independent models before they influence clinical practice. But the core message is clear and provocative: a single RNA-tagging enzyme can simultaneously build a faster-growing tumor and a blunter immune response, and undoing that dual sabotage may one day become a genuine therapeutic strategy against one of the world’s deadliest cancers.

Subject of Research: METTL16-mediated m6A modification of BCAT1 and branched-chain amino acid metabolism in colorectal cancer progression and CD8+ T cell immunity

Article Title: METTL16 promotes colorectal cancer progression and CD8+ T cell function through BCAT1-dependent branched-chain amino acid metabolism

Article References: Hu, Y., Li, S., Zhu, M., Lin, X., Gong, C., & Fang, Z. (2026). METTL16 promotes colorectal cancer progression and CD8+ T cell function through BCAT1-dependent branched-chain amino acid metabolism. Medical Oncology, 43(11), Article 295. https://doi.org/10.1007/s12032-026-03410-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03410-7

Keywords: colorectal cancer, METTL16, BCAT1, m6A modification, branched-chain amino acids, CD8+ T cells, immune evasion, tumor metabolism, RNA methyltransferase, immunotherapy resistance, xenograft model, cancer epigenetics

Inherited retinal dystrophies are a leading cause of irreversible blindness worldwide, and retinitis pigmentosa, the most common form, affects an estimated 2.5 million people. More than 100 causative genes have been identified, yet between 30 and 50 percent of cases still lack a genetic diagnosis, and the observation of incomplete penetrance hints that factors beyond DNA sequence are at work. Epigenetic mechanisms, which modulate gene expression without altering the genome, have increasingly come into focus in ocular disease. Among these, m6A stands out as the most abundant internal modification in eukaryotic messenger RNA, deposited by writer enzymes, removed by erasers such as FTO and ALKBH5, and interpreted by reader proteins that influence splicing, export, stability, and translation.

METTL16 is a relative newcomer to the m6A field. Unlike the well-known METTL3/METTL14 complex, it recognizes a specific motif, UACAGARAA, within structured RNA contexts, and its validated substrates include MAT2A mRNA, which it regulates to maintain cellular levels of the universal methyl donor S-adenosylmethionine, and U6 snRNA, a small nuclear RNA at the heart of the splicing machinery. METTL16 methylates U6 at position A43 within the ACAGAGA sequence that base-pairs with the 5′ splice site of introns during pre-mRNA splicing. Work in fission yeast, roundworms, plants, and human cells has shown that losing this modification impairs 5′ splice site recognition. Intriguingly, dominant mutations in U6 snRNA have recently been linked to autosomal dominant retinitis pigmentosa, and those variants cluster in regions that contact spliceosome components such as PRPF3, PRPF8, and PRPF31, proteins that are themselves mutated in RP.

To probe METTL16’s role in the retina, the team, led by Jiangbo Ren, Wenjing Liu, and colleagues, generated rod-specific Mettl16 knockout mice by crossing Mettl16-floxed animals with RHO-Cre mice, in which the recombinase is active only in rods. The resulting RKO mice showed efficient excision of the targeted exon and a marked reduction of METTL16 protein in the retina. Single-cell RNA sequencing data from the Human Protein Atlas had already indicated that METTL16 is broadly expressed across retinal cell types, with notable enrichment in rods, making the knockout strategy well suited to testing its function in the cells most vulnerable to retinitis pigmentosa.

The physiological consequences were swift and measurable. Electroretinograms recorded at one month of age revealed that scotopic responses, which reflect rod function, were severely blunted: a-wave and b-wave amplitudes were reduced by roughly 54 and 55 percent, respectively, compared with littermate controls. Cone-mediated photopic responses, by contrast, were largely preserved at this stage, pointing to a rod-first pattern of degeneration. Behavioral assays corroborated the electrophysiology. In a light-dark box test, RKO mice spent only about 39 percent of their time and traveled about 42 percent of their distance in the dark chamber, unlike control mice, which normally prefer darkness. Their optomotor response, a reflexive head movement that tracks rotating visual gratings, dropped to 1.56, well below the values of 2.0 or higher seen in controls.

Under the microscope, the story continued. At postnatal day 20, retinal architecture looked normal, but by day 30 the outer nuclear layer and outer segments of RKO retinas were visibly thinning, and by day 40 the outer nuclear layer had lost roughly 40 percent of its thickness relative to controls. Immunofluorescence showed that key outer segment proteins, including rhodopsin, PRPH2, GRK1, PDE6B, and CNGA1, were markedly reduced in abundance even though their localization within the photoreceptor was not disrupted. Signs of degenerative stress were everywhere: Müller glia became reactive, microglia adopted an amoeboid morphology and invaded the outer nuclear layer, and TUNEL staining detected apoptotic nuclei among the photoreceptors. Cones, meanwhile, showed only delayed involvement, with reduced M-opsin-positive cells appearing by day 40.

To trace the molecular roots of this collapse, the researchers integrated RNA sequencing with quantitative proteomics on one-month-old retinas. Among the genes concordantly downregulated at both the transcript and protein levels, Gene Ontology and KEGG analyses pointed squarely at photoreceptor development, photoreceptor cilia, inner and outer segments, visual perception, and the phototransduction cascade. Five established retinitis pigmentosa genes emerged from this analysis: Tulp1, Cnga1, Pde6g, Crb1, and Prcd. Four of them showed significant differential expression at both levels after correction for multiple testing, and the reductions were confirmed by RT-qPCR and Western blotting. The metabolic arm of the analysis revealed perturbations in the S-adenosylmethionine pathway as well, with Mat2a mRNA, a direct METTL16 substrate, reduced in knockout retinas, and Csad, a key enzyme of taurine biosynthesis, markedly decreased.

The mechanistic core of the paper lies in splicing. Using a single-base elongation and ligation-based qPCR assay called SELECT on purified U6 snRNA, the team confirmed that m6A at position A43 was reduced in knockout retinas. Transcriptome-wide analysis with rMATS then revealed extensive alternative splicing changes, with skipped exons as the predominant event class. Sequence analysis of affected 5′ splice sites showed a telling pattern: sites whose usage decreased in knockout retinas were enriched for adenosine at the +4 position, the very nucleotide engaged by methylated U6, and carried an RAG motif across the U6-interacting positions, whereas sites with increased usage favored stronger U5 snRNA base pairing and non-adenine nucleotides at +4. Crucially, aberrant splicing was already detectable at postnatal day 20, before any overt cell loss. Both Tulp1 and Pde6g, two established retinal dystrophy genes, showed increased exon skipping, and the affected donor sites shared the conserved //GURAG motif previously implicated in METTL16 loss in plants and worms. MeRIP-seq showed no change in m6A enrichment on the Tulp1 and Pde6g transcripts themselves, consistent with a U6-dependent mechanism rather than direct methylation of the mRNAs. The Tulp1 exon 4-skipped transcript is predicted to encode an in-frame deletion of 51 amino acids, and immunostaining revealed disrupted ribbon synapse architecture in knockout retinas, echoing the synaptic defects known from Tulp1 knockout mice.

The study also documented METTL16’s influence beyond the nucleus. MeRIP-seq identified Tor1b and Nlgn2 as candidate direct m6A targets, with reduced methylation in their 3′ untranslated regions and reduced expression in knockout retinas; luciferase reporter assays showed that wild-type METTL16 enhanced reporters bearing the wild-type 3′ UTRs but not motif-mutated versions, and a catalytic-domain-deficient METTL16 mutant failed to do so. In photoreceptor-derived 661W cells, loss of METTL16 accelerated the decay of both transcripts, indicating effects on mRNA stability. Meanwhile, immunoprecipitation coupled with mass spectrometry revealed that retinal METTL16 associates with translation factors including PURA, PABPC1, and EIF3B, and with the splicing factors SF3B1 and SF3B3. SUnSET assays and polysome profiling showed that Mettl16 knockdown reduced global translation efficiency in 661W cells, and polysome analysis confirmed diminished translational efficiency of phototransduction genes such as Cep164, Rpgr, Prph2, and Cnga1, whose mRNA levels were unchanged even as their proteins declined.

The authors are careful to note the limitations: most molecular analyses used bulk retinal tissue, which can blur cell-type-specific effects and mix primary METTL16-dependent events with secondary degenerative changes, and the mechanistic work relied on the 661W cell line because mature rods are difficult to manipulate in vitro. Catalytically dead rescue experiments and ribosome profiling will be needed to determine whether the translational role depends on methyltransferase activity. Even so, the picture that emerges is striking. METTL16, working in both the nucleus and the cytoplasm, appears to safeguard photoreceptors on at least three fronts: by methylating U6 snRNA to preserve splicing fidelity in dystrophy genes, by stabilizing specific m6A-marked transcripts, and by supporting the translation of the proteins that build the light-sensing machinery. Given that mutations in U6 snRNA and multiple spliceosome components cause retinitis pigmentosa in humans, the study suggests that RNA processing defects may be a broader and previously underappreciated theme in photoreceptor disease, one that could eventually inform diagnostic and therapeutic strategies for the many patients whose blindness still has no genetic explanation.

Subject of Research: The role of the m6A methyltransferase METTL16 in photoreceptor survival and retinal degeneration

Article Title: METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation

Article References: Ren, J., Liu, W., Zou, R., Sun, K., Yang, M., Zhu, X., & Yang, Z. (2026). METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.012

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.012

Keywords: METTL16, m6A, photoreceptors, retinitis pigmentosa, U6 snRNA, alternative splicing, RNA methylation, retinal degeneration, translation regulation, Tulp1, Pde6g, epitranscriptomics